This is a routine scientific conference update with no new data — no stock-moving catalyst. The next meaningful milestone is the Phase 2 stenoparib data readout (timing not specified) and the SCLC combo trial enrollment progress. Monitor for future clinical data releases or financing needs given the $21M market cap and pre-revenue status.
Price Chart
Executive Summary
Allarity Therapeutics announced a Trial-in-Progress poster presentation at the ESMO Gynaecological Cancers Congress 2026 for its Phase 2 study of stenoparib (dual PARP/WNT inhibitor) in platinum-resistant/ineligible ovarian cancer. The presentation is a routine scientific conference update with no new clinical data disclosed, and the company remains a pre-revenue clinical-stage biopharma with no financial results or guidance in this release.
Key Facts
- Poster 166TiP presented at ESMO Gynaecological Cancers Congress 2026 (June 17-19, Copenhagen) by PI Kathleen N. Moore, M.D.
- Trial-in-Progress design — no new clinical data included; only study design and rationale
- Stenoparib is a dual PARP1/2 and tankyrase 1/2 inhibitor targeting WNT pathway
- Phase 2 trial in platinum-resistant/ineligible ovarian cancer patients began enrolling summer 2025
- Separate Phase 2 trial for stenoparib + temozolomide in relapsed SCLC began enrolling early 2026 across multiple VA sites
- Allarity is pre-revenue, clinical-stage (Phase 2) with no disclosed revenue, EPS, or guidance
- Market cap ~$21M; 86% analyst bullish consensus; top holders include RenTech, Vanguard, State Street
Financial Impact
No financial data in release — pre-revenue clinical-stage biotech
Risk Factors
- No new clinical data in this poster — prior observations may not be confirmed in ongoing/future studies
- Pre-revenue company with limited cash runway; future financing risk if clinical milestones are delayed
- Stenoparib requires regulatory approval and DRP® companion diagnostic acceptance — both uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3314095 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $1.04 | awaiting T+20 | — | $0.9430 (−9.33%) |
Sep 29, 2026 28d ago | 8-K | $0.9651 | awaiting T+20 | — | $0.9430 (−2.29%) |
Sep 28, 2026 29d ago | Press Release | $0.9684 $0.9151 | ▼ −5.50% | ▼ −5.47% | $0.9430 (−2.62%) |
Sep 16, 2026 5w ago | 8-K | $1.16 $0.8699 | ▼ −24.68% | ▼ −27.86% | $0.9430 (−18.35%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $0.8601 | ▼ −26.49% | ▼ −28.75% | $0.9430 (−19.40%) |
Sep 11, 2026 6w ago | Press Release | $1.22 $0.9900 | ▼ −18.85% | ▼ −20.72% | $0.9430 (−22.70%) |
Aug 14, 2026 10w ago | Press Release | $1.37 $1.17 | ▼ −14.60% | ▼ −12.61% | $0.9430 (−31.17%) |
Jul 1, 2026 16w ago | 8-K | $1.33 $1.16 | ▼ −12.78% | ▼ −10.60% | $0.9430 (−29.10%) |
Jun 22, 2026 18w ago | 8-K | $1.36 $1.19 | ▼ −12.50% | ▼ −12.35% | $0.9430 (−30.66%) |
Jun 18, 2026 18w ago | Press Release | $1.43 $1.17 | ▼ −18.18% | ▼ −18.71% | $0.9430 (−34.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers